UK–US Drug Deal Raises Fear of £45bn NHS Raid

A UK–US pharmaceutical agreement could force the NHS to divert almost £45 billion from other services over the next decade unless additional funding is provided, according to a new medical analysis that has reignited claims that the health service has been drawn into a trade bargain with Washington.

The analysis warns that higher spending on new medicines, if funded from existing NHS budgets, could lead to an estimated 229,000 excess deaths in England by 2036. If the impact on adult social care is included, the estimate rises to 291,000 deaths.

The claim is based on modelling, not a present death toll. It does not suggest that the agreement itself directly kills patients. It argues that moving money from existing NHS services into higher drug spending would have severe consequences across a health system already struggling with waiting lists, hospital deficits, staff shortages and rising demand.

The agreement, published by the Government in April, commits Britain to increase spending on new medicines from 0.3 per cent of GDP in 2026 to 0.6 per cent by 2036. It also requires the UK to increase the share of the NHS budget spent on medicines from 10 per cent to 12 per cent and to raise the net price paid for new medicines.

In return, the United States has agreed not to impose tariffs on British pharmaceutical and medical technology exports for three years, from January 2026 until January 2029.

The Government says the arrangement will speed up access to innovative medicines for NHS patients, protect British pharmaceutical exports and support investment in the UK life-sciences sector. Ministers argue that patients in Britain have waited too long for new treatments and that the agreement will help make the UK a more attractive market for drug launches.

The NHS was not sold. It was repriced.

But the controversy has reopened one of the most sensitive questions in British politics: whether the NHS has been put into a trade negotiation despite repeated assurances that it would be protected.

The deal does not privatise the NHS. It does not transfer hospitals, staff or services to American companies. Its effect is more technical and potentially more far-reaching. It changes the pricing environment in which the NHS buys new medicines. It raises the level of spending expected on new drugs. It alters the threshold through which medicines are assessed for public funding.

The political charge is therefore not that the NHS has been sold. It is that the NHS has been repriced.

The central question is where the extra money will come from. If the Treasury provides new funding, ministers may argue that patients can receive faster access to new treatments without damage to other services. If the money has to come from existing NHS budgets, critics say the cost will be paid through fewer operations, fewer scans, longer waits, weaker primary care, reduced mental health provision and greater pressure on social care.

That is the basis of the mortality warning. Health spending is not abstract. Money spent on one form of treatment cannot be spent on another. A new cancer drug may extend life for one group of patients. A heart scan, a stroke unit, a district nurse, a GP appointment or a mental health bed may save life for another.

The Government’s difficulty is that the agreement appears to bind a major shift in NHS spending priorities to a wider trade and tariff negotiation with the United States.

A political commitment, not a treaty

The arrangement is not a full free trade agreement and is not treated as a binding treaty in the ordinary sense. It is a political commitment between the two governments. That makes it more flexible, but also raises questions about scrutiny. A significant change in the economics of NHS medicines has been made without the level of parliamentary examination that would normally accompany a formal treaty.

The American position has been clear. Washington has long argued that European health systems pay too little for new medicines and that American patients carry too much of the cost of pharmaceutical research and development. The UK agreement is intended to address what US officials describe as an imbalance in the way innovative drugs are funded.

For the British pharmaceutical industry, the deal offers a prize. Companies have argued for years that the UK’s medicines regime is too restrictive, that prices are too low, and that patients lose out because new drugs are not adopted quickly enough. The industry says the agreement could help bring more innovative medicines to NHS patients while strengthening Britain’s life-sciences competitiveness.

That is the strongest defence of the deal. Faster access to effective medicines is not trivial. For patients with advanced cancers, rare genetic disorders or severe autoimmune disease, delays in approval can mean the difference between treatment and decline. A richer medicines market may also encourage investment, research and high-skilled employment in Britain.

But the opposing case is equally serious. The NHS is a finite public system. Its purpose is to allocate resources according to health need and cost-effectiveness, not to satisfy the commercial expectations of multinational drug companies or the trade demands of a foreign government.

The dispute therefore turns on a hard question: will paying more for new medicines produce better health outcomes than spending the same money elsewhere in the health service?

That question has not been answered.

The hidden cost of faster access

The Government can argue that the critics are assuming the worst-case scenario. Future spending reviews may provide additional money. The full cost may be lower than feared. New drugs may reduce pressure elsewhere in the system by keeping patients healthier for longer. The deal may protect exports, jobs and research investment in a sector where Britain wants to remain globally competitive.

But ministers have not yet removed the suspicion that NHS spending priorities have been altered as the price of tariff protection from Washington.

That suspicion is politically dangerous because it cuts across an old promise. British governments have repeatedly insisted that the NHS would not be used as a bargaining chip in trade talks. The published agreement allows ministers to say, narrowly, that the NHS has not been sold. It does not allow them to say that the NHS has been untouched.

Its medicines budget has been tied to an international bargain. Its pricing rules have been changed. Its assessment system has been adjusted. Its future spending priorities may now be shaped by a deal designed partly to satisfy American concerns over drug prices.

The immediate battle will be over funding. If the extra cost is covered by new money, the Government may survive the charge that it has raided existing care to fund higher drug prices. If it is not, the argument will move from trade policy to hospital wards, GP surgeries and waiting lists.

The deeper issue is constitutional. A decision of this scale should not be buried in the machinery of a pharmaceutical arrangement. It changes how the NHS values medicines, how public money is allocated and how far British health policy can be pulled into the orbit of American trade pressure.

Until ministers explain who pays, what services are protected and why Parliament was not given fuller control over the process, the controversy will continue.

The NHS was not sold. That is too crude. The more uncomfortable point is that it may have been repriced — and the bill may now fall on patients who never knew the bargain had been made.